Insulet
PODD
Market cap $20.4B

289.32 USD

-8.08

2.72%

At close Jul 11, 4:00 PM EDT

After hours

289.32

+0.00

0.00%

1 day

-2.72%

5 days

-3.47%

1 month

-4.27%

3 months

13.91%

6 months

7.96%

Year to date

12.64%

1 year

42.09%

5 years

49.13%

10 years

800.19%

About: Insulet was founded in 2000 with the goal of making continuous subcutaneous insulin infusion therapy for diabetes easier to use. The result was the Omnipod system, which consists of a small disposable insulin infusion device and that can be operated through a smartphone to control dosage. Since the Omnipod was approved by the US Food and Drug Administration in 2005, approximately 500,000 insulin-dependent diabetics are using it worldwide.

Employees: 3,900

Healthcare Medical Devices

0

Funds holding %

of 7,312 funds

0

Analysts bullish %

of 7 analysts

Fund manager confidence

Based on 2025 Q1 regulatory disclosures by fund managers ($100M+ AUM)

94% more first-time investments, than exits

New positions opened: 91 | Existing positions closed: 47

31% more repeat investments, than reductions

Existing positions increased: 291 | Existing positions reduced: 222

4% more funds holding

Funds holding: 671 [Q4 2024] → 699 (+28) [Q1 2025]

0% more funds holding in top 10

Funds holding in top 10: 5 [Q4 2024] → 5 (+0) [Q1 2025]

0% less capital invested

Capital invested by funds: $18.4B [Q4 2024] → $18.3B (-$67.3M) [Q1 2025]

1.21% less ownership

Funds ownership: 100.42% [Q4 2024] → 99.21% (-1.21%) [Q1 2025]

32% less call options, than puts

Call options by funds: $103M | Put options by funds: $150M

See Fund Rankings

Research analyst outlook

7 Wall Street Analysts provided 1 year price targets over the past 3 months

Low target

$266

8%

downside

Avg. target

$346

20%

upside

High target

$380

31%

upside

7 analyst ratings

6 positive

86%

1 neutral

14%

0 negative

0%

Truist Securities Richard Newitter	26%upside $365	Buy Initiated	16 Jun 2025
Goldman Sachs David Roman	31%upside $380	Buy Initiated	30 May 2025
Raymond James Jayson Bedford	24%upside $360	Outperform Maintained	27 May 2025
Citigroup Joanne Wuensch	31%upside $380	Buy Maintained	22 May 2025
Wolfe Research Mike Polark	21%upside $350	Outperform Upgraded	13 May 2025

See Analyst Rankings

Financial journalist opinion

Based on 5 articles about PODD published over the past 30 days

Zacks Investment Research

Will Insulet (PODD) Beat Estimates Again in Its Next Earnings Report?

Insulet (PODD) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

Will Insulet (PODD) Beat Estimates Again in Its Next Earnings Report?

Insulet to Announce Second Quarter 2025 Financial Results on August 7, 2025

ACTON, Mass.--(BUSINESS WIRE)--Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, today announced it will report financial results for the second quarter of 2025 on August 7, 2025, before the opening of the financial markets. In connection with the release, management will host a conference call that day at 8:00 a.m. (Eastern Time). The link to the live call will be available on the Investor Rel.

Insulet to Announce Second Quarter 2025 Financial Results on August 7, 2025

Investors Business Daily

Why Diabetes Titans Dexcom, Tandem, Insulet Just Hit The Skids

Shares of Dexcom, Tandem Diabetes and Insulet skidded Tuesday on a proposal that would cut Medicare reimbursements for wearable diabetes tech.

Why Diabetes Titans Dexcom, Tandem, Insulet Just Hit The Skids

The Motley Fool

10 Under-the-Radar Healthcare Stocks With Incredible Growth Potential

There's a strong case that healthcare is the most important sector in the stock market. These companies deliver innovative therapies and medical technologies that are often life-saving.

10 Under-the-Radar Healthcare Stocks With Incredible Growth Potential

Insulet to Share Additional Evidence Demonstrating the Impact of Omnipod® 5 on Improved Health Outcomes at the American Diabetes Association 85th Scientific Sessions

ACTON, Mass.--(BUSINESS WIRE)--Insulet to Share Additional Evidence Demonstrating the Impact of Omnipod 5 on Improved Health Outcomes at the American Diabetes Association Conference.

Insulet to Share Additional Evidence Demonstrating the Impact of Omnipod® 5 on Improved Health Outcomes at the American Diabetes Association 85th Scientific Sessions

Zacks Investment Research

Here's Why You Should Retain PODD Stock in Your Portfolio Now

Insulet's Omnipod 5 gains traction with global expansion and rising Type 2 adoption despite economic and competitive hurdles.

Here's Why You Should Retain PODD Stock in Your Portfolio Now

20 stocks bucking bad trends on Wall Street — what might be next for them?

Analysts have been cutting their estimates for companies' sales and profits, but there are always exceptions to trends.

20 stocks bucking bad trends on Wall Street — what might be next for them?

Insulet's Omnipod® 5 App for iPhone with Dexcom G7 Integration Now Available to all U.S. Users

ACTON, Mass.--(BUSINESS WIRE)--Insulet Corporation (NASDAQ: PODD), the global leader in tubeless insulin pump technology, is excited to announce that the Omnipod® 5 App for iPhone is now compatible with the Dexcom G7 Continuous Glucose Monitoring (CGM) System. With this latest integration, the Omnipod 5 Automated Insulin Delivery (AID) System combines the benefits of tubeless AID and Dexcom's latest diabetes management technology, all conveniently controlled from an iPhone. "This integration re.

Insulet's Omnipod® 5 App for iPhone with Dexcom G7 Integration Now Available to all U.S. Users

20 stocks of companies that have improved profit margins and are expected to grow quickly

These companies are more profitable than they were a year ago. They are also expected to put up huge sales growth numbers through 2027.

20 stocks of companies that have improved profit margins and are expected to grow quickly

3 Medical Technology Stocks Outperforming in 2025

As the broader market stages a sharp rebound from its April lows, several sectors, industries, and stocks have quietly emerged as leaders. Among them, the medical technology industry, known for its innovation and growth potential, has stood out.

3 Medical Technology Stocks Outperforming in 2025

See News Rankings

Charts implemented using Lightweight Charts™